G&E Herbal Biotechnology Co., Ltd. (Taiwan)
Corporate brand
UnclaimedTaiwanese botanical new-drug developer and manufacturer of plant-based pharmaceuticals, health foods and cosmetics, listed on the Taipei Exchange under ticker 4911.
Last updated September 26, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
G&E Herbal Biotechnology Co., Ltd. (德英生物科技股份有限公司) is a Taiwanese botanical pharmaceutical company headquartered in the Southern Taiwan Science Park in Tainan. Founded in August 2002 (the 91st year of the Republic of China calendar) by Professor Kuo Kuo-Hua, a former 23-year faculty member of the Department of Biochemistry at Kaohsiung Medical University, the company was approved in October 2002 as a high-technology enterprise permitted to establish a plant in the Southern Taiwan Science Park. Its name derives from the brand story: "G" from Gaia, the earth goddess who nurtures all things, and "E" from Eternity, expressing the principle of endless regeneration. The company positions itself as a fully integrated botanical new-drug developer. It has built in-house facilities covering botanical extraction, botanical active pharmaceutical ingredient (API) production, a PIC/S GMP pharmaceutical plant, a food plant and a GMP cosmetics plant. From contract farming with farmers through extraction, manufacturing and quality control, the entire chain is completed within the company. Its stated mission is to apply natural plant resources to treat diseases that currently lack effective clinical therapies, including cancers, hepatobiliary and renal diseases, dry eye and floaters, skin itching, dialysis fistula patency and swelling, and bone and muscle strengthening. G&E's lead new drug candidate is SR-T100, a plant-derived candidate developed for actinic keratosis (squamous cell carcinoma in situ), genital warts and malignant ascites in late-stage cancer patients. The company reports that SR-T100 gel has completed Phase III human clinical trials in Taiwan and a US FDA-approved Phase II trial, and that an injectable formulation for malignant ascites is under development. Its products also include the liver-related drug Hepanamin® (利保肝), the health-food line Antila® and the skincare line GlitEr®. The company states that its Silymarin product has achieved the world's highest pharmacopoeial dissolution rate. G&E was approved for OTC listing by the ROC Securities and Futures Commission (GreTai Securities Market) on 21 March 2011 and trades under ticker 4911. It reports paid-in capital of NT$688,171,330 and states that it has no external investments or bank loans, with all plant and land self-purchased. The company has received numerous awards, including the National Invention and Creation Award, the Golden Award of the Drug Technology Research and Development Award, and the 2025 Foreign Investment Selected Taiwan Top 100 awards. It has signed international distribution agreements, including a world-exclusive agency contract for Hepanamin with Bama International in 2022 and a Taiwan exclusive agency contract for "Miao Jing Liang" with Golden Phoenix International in 2023. Hepanamin has been exported to Singapore and won a Malaysian health brand award.
History
G&E Herbal Biotechnology Co., Ltd. was founded in August 2002 (the 91st year of the Republic of China calendar) by Professor Kuo Kuo-Hua, who had served for 23 years in the Department of Biochemistry at Kaohsiung Medical University and accumulated more than 46 years of drug development experience. In October 2002, the company was approved by the Executive Yuan's Ministry of Science and Technology as a high-technology enterprise and was permitted to establish its plant in the Southern Taiwan Science Park. The company's name reflects its founding philosophy: "G" from Gaia, the earth goddess who nurtures all things, and "E" from Eternity, representing the principle of endless regeneration. The brand story recounts that in 2001 a letter from the Department of Chinese Medicine and Pharmacy of the Department of Health invited Professor Kuo to a press conference announcing his US anticancer drug patent, which led him to meet many cancer patients and ultimately to leave academia to pursue new drug development. G&E built an integrated infrastructure covering botanical extraction, botanical API production, a PIC/S GMP pharmaceutical plant, a food plant and a GMP cosmetics plant. Its research team spans biochemistry, physiology, molecular biology, pharmacology, plant horticulture, animal testing and quality control analysis. The company's lead candidate, SR-T100, has been developed for actinic keratosis, genital warts and malignant ascites. According to the company history, in 2007 the Phase II clinical development plan for SR-T100 gel for skin cancer was approved; in 2008 the company was registered on the Emerging Stock Board of the GreTai Securities Market under ticker 4911; in 2009 it completed Phase II enrollment for actinic keratosis and obtained EU and Canadian invention patents; in 2010 it collaborated with National Cheng Kung University on the national biotechnology pharmaceutical program for plant candidate new drug SR-100 and received SNQ national quality certification; in 2011 it was approved for OTC listing on 21 March 2011 and received the National Invention and Creation Award gold medal; in 2012 it received the Golden Award of the Drug Technology Research and Development Award; in 2013 it obtained drug licenses for "Gan Huo Su Capsule 150 mg", "Hepanamin Capsule 70 mg" and "Kang Ai Xin Gan Capsule", as well as medical device licenses for "Si Mi Gel" and "You Le Gel"; in 2014-2015 it obtained invention patents for treating or preventing skin aging and inflammation in Korea, Australia, Russia, Japan, Taiwan and the US; in 2016 its Phase III clinical trial final report for SR-T100 was approved by the Department of Health; in 2018 the new PIC/S GMP formulation plant was completed and passed on-site inspection, and the US FDA approved a Phase II human trial of SR-T100 ointment; in 2019 the PIC/S GMP plant was approved, a European patent for treating or preventing skin aging and inflammation was granted, Hepanamin was exported to Singapore, and distribution contracts were signed with Eastern Home Shopping and Tianmeishi; in 2020 the food plant received PIC/S GMP co-manufacturing food certification; in 2021 a memorandum of cooperation was signed with Japan's S-Link and the Taiwan Phase III clinical trial for SR-T100 gel for actinic keratosis was recommended as a continuation case under the Ministry of Economic Affairs A+ Enterprise Innovation Program; in 2022 a world-exclusive agency contract for Hepanamin was signed with Bama International; in 2023 a Taiwan exclusive agency contract for "Miao Jing Liang" was signed with Golden Phoenix International and Hepanamin won the Malaysian Health Brand Award; in 2024 the SR-T100 injection was submitted to the Ministry of Health and Welfare for human clinical trial consultation; and in 2025 Hepanamin capsules (70 mg) completed three batches of 48-month long-term stability testing with a four-year shelf life, and the company received three 2025 Foreign Investment Selected Taiwan Top 100 awards. The company states that it has no external investments or bank loans, that its plant and land are fully self-purchased, and that its paid-in capital is NT$688,171,330. It has received numerous awards including the National Invention and Creation Award, the Drug Technology Golden Award, the 2010 Taipei Biotech Award gold medal, and the 2025 Foreign Investment Selected Taiwan Top 100 awards (Mid-Cap Potential Enterprise Award, Growth Top 10 Award, Profit Top 10 Award).
- 2025
Hepanamin capsules (70 mg) completed 48-month long-term stability testing; received three 2025 Foreign Investment Selected Taiwan Top 100 awards.
- 2024
SR-T100 injection submitted to the Ministry of Health and Welfare for human clinical trial consultation.
- 2023
Signed Taiwan exclusive agency contract for "Miao Jing Liang" with Golden Phoenix International; Hepanamin won Malaysian Health Brand Award.
- 2022
Signed world-exclusive agency contract for Hepanamin with Bama International.
- 2021
Signed memorandum of cooperation with Japan's S-Link; SR-T100 gel Phase III trial recommended under MOEA A+ program.
- 2020
Food plant received PIC/S GMP co-manufacturing food certification.
- 2019
PIC/S GMP plant approved; European patent granted; Hepanamin exported to Singapore; distribution contracts signed with Eastern Home Shopping and Tianmeishi.
- 2018
New PIC/S GMP formulation plant completed and passed inspection; US FDA approved Phase II human trial of SR-T100 ointment.
- 2016
Phase III clinical trial final report for SR-T100 approved by the Department of Health.
- 2015
Obtained invention patents for treating or preventing skin aging and inflammation in Japan and Taiwan.
Products and positioning
Fully integrated Taiwanese botanical new-drug developer with in-house cultivation, extraction, PIC/S GMP manufacturing and clinical development capabilities.
SR-T100
Botanical new drug candidate developed for actinic keratosis, genital warts and malignant ascites; gel and injectable formulations.
Hepanamin® (利保肝)
Liver-related botanical drug; exported to Singapore and Malaysia; world-exclusive agency with Bama International.
Antila®
Health food line based on natural plant extracts.
GlitEr®
Skincare line using patented botanical ingredients for skin aging prevention.
Silymarin
Product with the world's highest pharmacopoeial dissolution rate, used for hepatobiliary and renal diseases.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/g-and-e-herbal-biotechnology-co-ltd-taiwan · Editorial policy · How profiles are compiled